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Smoking, DNA Methylation, and Lung Function:
a Mendelian Randomization Analysis
to Investigate Causal Pathways
Emily Jamieson,1,2 Roxanna Korologou-Linden,1,2 Robyn E. Wootton,1,3,4 Anna L. Guyatt,5
Thomas Battram,1,2 Kimberley Burrows,1,2 Tom R. Gaunt,1,2,4 Martin D. Tobin,5 Marcus Munafo`,1,3,4
George Davey Smith,1,2,4 Kate Tilling,1,2 Caroline Relton,1,2 Tom G. Richardson,1,2
and Rebecca C. Richmond1,2,*
Whether smoking-associated DNA methylation has a causal effect on lung function has not been thoroughly evaluated. We first inves-
tigated the causal effects of 474 smoking-associated CpGs on forced expiratory volume in 1 s (FEV1) in UK Biobank (n ¼ 321,047) by
using two-sampleMendelian randomization (MR) and then replicated this investigation in the SpiroMeta Consortium (n¼ 79,055). Sec-
ond, we used two-step MR to investigate whether DNA methylation mediates the effect of smoking on FEV1. Lastly, we evaluated the
presence of horizontal pleiotropy and assessed whether there is any evidence for shared causal genetic variants between lung function,
DNA methylation, and gene expression by using a multiple-trait colocalization (‘‘moloc’’) framework. We found evidence of a possible
causal effect for DNA methylation on FEV1 at 18 CpGs (p < 1.2 3 10
4). Replication analysis supported a causal effect at three CpGs
(cg21201401 [LIME1 and ZGPAT], cg19758448 [PGAP3], and cg12616487 [EML3 and AHNAK] [p < 0.0028]). DNA methylation did
not clearly mediate the effect of smoking on FEV1, although DNA methylation at some sites might influence lung function via effects
on smoking. By using ‘‘moloc’’, we found evidence of shared causal variants between lung function, gene expression, and DNAmethyl-
ation. These findings highlight potential therapeutic targets for improving lung function and possibly smoking cessation, although
larger, tissue-specific datasets are required to confirm these results.Introduction
Cigarette smoking is a major risk factor for lung disease,
which is often preceded by a rapid decline in lung func-
tion.1 Studies have shown a strong causal role of smoking
in relation to lung-function decline, which can be
measured by forced expiratory volume in 1 s (FEV1).
2
Exploring the mechanistic pathways leading to decreased
lung function in smokers could highlight targets for thera-
peutic intervention.
One mechanism that might mediate the association be-
tween smoking and decreased lung function is altered
DNAmethylation patterns. Smoking is associatedwith sub-
stantial changes to methylation levels at many loci across
the genome.3 For example, hypomethylation at the CpG
site cg05575921 in intron 3 of the aryl hydrocarbon recep-
tor repressor (AHRR) gene is strongly associated with both
the current and past smoking behavior of an individual,3,4
and it has recently been suggested to mediate a proportion
of the effect of smoking on decreased lung function.5 How-
ever, it is not clear that this association represents a true
causal pathway.6 Furthermore, DNA methylation at other
CpG sites related to lung function might also serve as a po-
tential mediator on the pathway from smoking.7,8
Mendelian randomization (MR) is a method that re-
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 2020 American Society of Human Genetics.exposure on an outcome9 by using genetic variants
robustly associated with the exposure as proxies. Because
genetic variants are effectively randomized at conception,
they are unlikely to be influenced by confounding factors
that might otherwise bias associations in observational
analysis. In the context of methylation, MR is facilitated
by genetic variants, known as mQTLs (methylation quan-
titative trait loci), that are found to be strongly associated
with DNA methylation.10
Among the many extensions of the basic MR principle11
is the two-step method, which aims to assess whether an
intermediate factor has a causal role in the mediating
pathway between the exposure and the outcome.12 A
further extension is the two-sample framework, which al-
lows the exposure and outcome data to come from two in-
dependent datasets so that the effect of the genetic variant
on the exposure and outcome can be estimated sepa-
rately.13 Both approaches are particularly advantageous
for epigenetic studies: two-step MR can be used so that
DNA methylation might serve as an intermediate between
a particular exposure and outcome, and two-sample MR
can be used because DNAmethylation datasets are unlikely
to include the relevant exposure and/or outcome data of
interest. Researchers can use these methods to evaluate
the causal role of DNA methylation at a large number of
CpG sites; they can also use these methods within af Bristol, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8
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ation mediates the effect of an exposure and outcome.12,14
A key violation of the MR approach is horizontal pleiot-
ropy, whereby a genetic variant used to proxy a modifiable
exposure is associated with the outcome through pathways
not involving the exposure.Various sensitivity analyses exist
for investigating horizontal pleiotropy in MR analysis,15
which can also be applied to assessing the validity ofmQTLs
as genetic proxies for DNAmethylation and can be comple-
mented by colocalization approaches16 that help to evaluate
whether the mQTL is responsible for effects on both DNA
methylation and theoutcome.17 Furthermore,multiple-trait
colocalization (‘‘moloc’’) can also be used for determining
whether variation in DNA methylation levels at putatively
causal CpG sites might influence traits via changes in the
expression of nearby genes.18 Such approaches can be inte-
grated into an analytical pipeline that can be used for high-
lighting and prioritizing molecular pathways for further
intervention.19
We first aimed to search for a causal effect of methylation
at smoking-associated CpG sites on FEV1 in the UK Bio-
bank by using two-sample MR, and we replicated this
search in the SpiroMeta Consortium.20 Second, we investi-
gated whether DNA methylation mediates the effect of
smoking on FEV1. Lastly, we evaluated the presence of hor-
izontal pleiotropy and also assessed whether there is any
evidence for shared causal genetic variants between lung
function, DNA methylation, and gene expression by using
a ‘‘moloc’’ framework.Material and Methods
mQTL Identification: The Accessible Resource for
Integrated Epigenomic Studies in the Avon Longitudinal
Study of Parents and Children
The Avon Longitudinal Study of Parents and Children (ALSPAC) is
a large, prospective cohort study based in the southwest of En-
gland. A total of 14,541 pregnant women who were residing in
Avon, UK, and had expected dates of delivery from April 1, 1991
to December 31, 1992 were recruited, and detailed information
has been collected on these women and their offspring at regular
intervals.21,22 The study website contains details of all the data
that are available through a fully searchable data dictionary. Writ-
ten informed consent has been obtained for all ALSPAC partici-
pants. Ethical approval for the study was obtained from the
ALSPAC Ethics and Law Committee and the local research ethics
committees.
As part of the Accessible Resource for Integrated Epigenomics
Studies (ARIES) project,10,23 the Illumina Infinium HumanMethy-
lation450 (HM450) BeadChip was used for generating epigenetic
data on cord blood and peripheral blood samples from 1,018
mother-offspring pairs in the ALSPAC cohort at five time points
(birth, childhood, adolescence, the antenatal period, and middle
age). The ARIES participants were previously genotyped as part
of the larger ALSPAC study, and quality control, cleaning,
and imputation were performed at the cohort level as described
previously.102 The American Journal of Human Genetics 106, 1–12, March 5, 202Matrix eQTL software24 was used for preliminary association
analysis of SNPs with CpG sites in the HM450 array; further multi-
variable linear regression analysis was run in PLINK1.07,25 and
genome-wide complex trait analysis (GCTA) was performed26 as
previously described10 so that conditionally independent mQTLs
could be determined. Associations with p< 13 107 were selected
for this analysis via a publicly available online catalog.10 For this
analysis, we only considered those mQTLs identified in the mid-
dle-age time point among women in ARIES.Genome-wide Association of Forced Expiratory Volume
and Lifetime Smoking Behavior: UK Biobank
We used genetic association data from individuals in the UK Bio-
bank. The UK Biobank study is a large population-based cohort of
502,682 individuals who were recruited at ages 37–73 years across
theUKbetween 2006 and 2010; the study includes extensive health
and lifestylequestionnairedata (including smokingbehavior),phys-
ical measures (including spirometry), and DNA samples. The study
protocol is available online, and more details have been published
elsewhere.27 The UK Biobank study was approved by the North
West Multi-Centre Research Ethics Committee (reference number
06/MRE08/65), and at recruitment, all participants gave informed
consent to participate in the UK Biobank and be followed-up with.
Participants were genotyped with either the Affymetrix UK
BiLEVE Axiom Array or the Affymetrix UK Biobank Axiom Array.
Details of how the genotype data were cleaned, imputed, and
released to the scientific community are detailed elsewhere.28
Summary-level genetic association statistics for FEV1 were ob-
tained from a recent genome-wide association study (GWAS) of
FEV1 (covariate adjusted and inverse-normal rank transformed)
in the UK Biobank (n ¼ 321,047)20 and, for lifetime smoking
behavior, from a GWAS of a comprehensive smoking index metric
derived from data on smoking duration, heaviness, and cessation
in UK Biobank participants (n ¼ 462,690)29.Two-Sample MR: ARIES and UK Biobank
To assess the causal effect of DNA methylation at smoking-related
CpG sites on lung function, we conducted two-sample MR.13 In
this approach, information on the SNP-exposure (here, DNA
methylation) and SNP-outcome (here, lung function [FEV1]) effects
are derived from genome-wide association analysis conducted in
separate studies with the ‘‘TwoSampleMR’’ package in R15.
For the smoking-related CpG sites that could be proxied by
mQTLs, we looked up the identified mQTLs in the lung function
GWAS summary data from the UK Biobank. We extracted the
following summary data for each SNP: the effect estimate, along
with its standard error (SE), for lung function per copy of the
effect allele, the reference allele, and the effect allele along with
its frequency. We combined information on the SNP-lung func-
tion associations from the UK Biobank with information on the
SNP-methylation associations from ARIES in order to perform
the Mendelian randomization analysis described below.
For each SNP, we calculated the change in FEV1 per standard de-
viation (SD) increase in methylation by the formula bGD/bGP
(also known as a Wald ratio), where bGD is the SD change in vol-
ume of air exhaled in 1 s per copy of the effect allele and where
bGP is the SD increase in methylation per copy of the effect allele.
SEs of the Wald ratios were approximated by the delta method.30
Where multiple conditionally independent mQTLs were available
for the same CpG site, we combined these in a fixed effects
meta-analysis after weighting each ratio estimate by the inverse0
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Replication: SpiroMeta
We attempted to replicate the findings regarding the causal effect
of DNA methylation by using an independent second sample for
the two-sample MR approach. For this, we used data available on
genetic variants and lung function (FEV1) in 79,055 individuals
of European ancestry from 22 studies, combined in a meta-anal-
ysis by the SpiroMeta Consortium.20
Stratification: UK BiLEVE
To investigate the extent to which the genetically predicted effects
of DNA methylation on lung function are modified by smoking
status, we conducted an MR analysis stratified by smoking status.
For this, GWAS of FEV1 has been undertaken in 48,931 individuals
from the UK BiLEVE study, involving a subset of UK Biobank par-
ticipants who were selected from the extremes of the lung-func-
tion distribution (extremely low, near average, and extremely
high) and by smoking status (never versus heavy smokers [mean
of 35 pack-years of smoking, where 1 pack-year is equal to smoking
20 cigarettes (1 pack) per day for 1 year]).31,32 Genotyping was un-
dertaken with the Affymetrix Axiom UK BiLEVE array for 24,457
smokers and 24,474 non-smokers in the UK BiLEVE study.
Causal Effects of DNA Methylation on Other Lung-
Function-Related Traits
We assessed consistency of the causal effects observed for FEV1 in
relation to a number of other lung-function-related traits by using
summary statistics from a UK Biobank GWAS20 of forced vital ca-
pacity (FVC) (n ¼ 321,047) and FEV1/FVC ratio (n ¼ 321,047), as
well as from other UK Biobank GWAS33 of self-reported asthma
(n ¼ 53,598 cases, 409,335 controls), self-reported chronic
obstructive pulmonary disease (COPD) (n ¼ 1,605 cases, 461,328
controls), and COPD derived from ICD-10 codes (n ¼ 3,871 cases,
459,139 controls).
DNA Methylation and Lung Function: Direction of
Causality
Where there was evidence that DNA methylation might have a
causal effect on lung function, we evaluated the possibility of
reverse causation, whereby a SNP used as a proxy for DNAmethyl-
ation has its primary effect through lung function rather than
through DNA methylation. For this, we performed the MR Steiger
test,34 implemented in the ‘‘TwoSampleMR’’ package15 with the
previously outlined summary GWAS data from ARIES and the
UK Biobank, to determine the likely direction of effect.
Furthermore, we conducted the reciprocal MR at these CpG sites
to appraise the causal effect of lung function (FEV1) on DNA
methylation. For this, we assessed associations between 221
SNPs with p < 5 3 108 from the UK Biobank GWAS of FEV1
and DNA methylation at the CpG sites of interest identified in
the middle-age time point among women in ARIES. Because
only associations with p < 1 3 107 were available in the publicly
available online catalog, we used PLINK1.0710 to perform exact
linear regression of methylation beta-values at each CpG site on
SNP genotypes and also adjusted the model for age, sex, top ten
ancestry principal components, bisulphite conversion batch,
and estimated white blood cell counts.TheSmoking Behavior and DNA Methylation: Direction of
Causality
We also performed bidirectional MR to evaluate the direction of ef-
fect between lifetime smoking behavior and DNA methylation at
the identified CpG sites. For lifetime smoking behavior, we ob-
tained summary statistics for 126 independent SNPs identified in
a GWAS of comprehensive smoking index,29 with p < 5 3 108.
We looked up these SNPs in a GWAS of DNA methylation at the
CpG sites of interest, as described above. We then conducted MR
to appraise the causal effect of lifetime smoking behavior on
DNA methylation. We also looked up mQTLs that proxied for
DNA methylation at the CpG sites of interest in the summary
data from the GWAS of lifetime smoking behavior and conducted
another two-sample MR analysis to appraise the causal effect of
DNA methylation on lifetime smoking behavior.
Negative Control
We also assessed the association between the mQTL and DNA
methylation at the CpG sites of interest by using data from
the childhood time point of ALSPAC and exact linear regression
as described above. This can be viewed as a negative-control
analysis assessing the specificity of the mQTL effect on DNA
methylation because the association should not be present in
this group of non-smoking individuals if it is driven by smoking
behavior.
Mediation Analysis
For those CpG sites where there was consistent evidence that
methylation had a causal effect on lung function and where life-
time smoking was also causally implicated, we used a two-step
MR approach12 to investigate mediation. Prior to this, we per-
formed anMR analysis to estimate the total causal effect of lifetime
smoking behavior on lung function by looking up the SNPs asso-
ciated with lifetime smoking behavior in the GWAS summary data
for FEV1.
For those CpGs where there was evidence that smoking influ-
enced DNA methylation, which in turn influenced lung function,
we used the ‘‘product of coefficients’’ method35 to obtain an esti-
mate for the indirect effect of smoking on lung function via
DNA methylation. For those CpGs where there was evidence
that, conversely, DNA methylation influenced smoking, which
in turn influenced lung function, we used the ‘‘product of coeffi-
cients’’ method to obtain an estimate for the indirect effect of
DNA methylation on lung function via smoking. This approach
is outlined in Figure 1. Standard errors for the indirect effect
were derived by using the delta method.
Another MR approach that can be used for assesingmediation is
multivariable MR (MVMR).36,37 This approach can help re-
searchers to determine the direct effect of an exposure on an
outcome, which can be subtracted from the total effect to obtain
an estimate for the indirect effect (‘‘difference in coefficients
method’’).35 We used MVMR to estimate the direct effects of life-
time smoking and the identified CpG sites on lung function by
including the genetic proxies for smoking and each CpG site in
turn in the multivariable models. SEs for the indirect effect were
derived with the delta method.
Evaluating Horizontal Pleiotropy
Although various sensitivity analyses for investigating horizontal
pleiotropy in MR analysis exist,15 these approaches typically rely
upon the existence of multiple genetic proxies associated withAmerican Journal of Human Genetics 106, 1–12, March 5, 2020 3
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Figure 1. Outline of the Steps of the Mediation Analysis
(A) Assessment of the mediating role of DNA methylation in the
effect of smoking behavior on lung function (FEV1).
(B) Assessment of the mediating role of smoking behavior in the
effect of DNA methylation on lung function (FEV1). q1 ¼ step 1;
q2¼ step 2; indirect effect¼ q13 q2 (product of coefficients); direct
effect ¼ q3; total causal effect ¼ q3 þ q1 x q2.
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mQTLs are usually associated with individual CpG sites, it is often
difficult to evaluate horizontal pleiotropy. To overcome this, we
used an approach whereby we could examine multiple mQTLs
in linkage disequilibrium (r2 < 0.8) as instruments for a given
CpG site and incorporated the correlation of the mQTLs as
weights in a weighted generalized linear regression.38 This was per-
formed with summary statistics fromMatrix eQTL,10 as well as the
‘‘LDlink’’ and ‘‘MendelianRandomization’’ packages in R (version
3.5.1). Further to this, we assessed overall horizontal pleiotropy
by (1) quantifying the heterogeneity of the genetic variants based
on the Q statistic by using modified weights for the IVW
approach,39 as well as theMR-PRESSO global test,40 and (2) testing
the intercept in the MR-Egger test.41 To account for horizontal
pleiotropy, we performed two additional MR analyses that make
different assumptions about this: (1) MR Egger regression41 and
(2) the weighted median approach.42 The following R packages
were used for these analyses: ‘‘Mendelian Randomization,’’ ‘‘Radi-
alMR,’’ and ‘‘MR-PRESSO.’’
Multiple-Trait Colocalization Analysis
For those CpG sites where there was evidence of a causal effect on
lung function, we applied (‘‘moloc’’)18 to investigate whether the
variant responsible for influencing methylation at each CpG site
was the same variant influencing changes to both nearby gene
expression and lung function.17,43 We applied ‘‘moloc’’ by using
data derived from three different sources: mQTL data from the
middle-age time point (mean age 47.5 years) in ARIES, GWAS sum-
mary data for FEV1 from the UK Biobank,
20 and expression quan-
titative-trait loci (eQTL) data derived from whole blood from the
eQTLGen Consortium (n ¼ 31,684).44 We ran ‘‘moloc’’ multiple
times to investigate colocalization with the expression of all genes
within 1 Mb of the CpG site of interest. Analyses were only under-
taken if there were at least 50 variants (minor-allele frequency
[MAF] R 5%) in common between all three datasets. As recom-
mended by the developers of ‘‘moloc’’, a posterior probability of
association (PPA) of 80% or higher was considered evidence of co-
localization. This approach therefore suggests that loci with evi-
dence of genetic colocalization harbor a single causal variant
that is responsible for variation in DNAmethylation, gene expres-
sion, and lung function. When there was evidence at the same4 The American Journal of Human Genetics 106, 1–12, March 5, 202locus with multiple genes, we reported the association with the
highest PPA. All analyses were undertaken with R (version 3.5.1).Results
Analysis Pipeline
A summary of the analysis pipeline used to investigate the
causal effect of DNA methylation on lung function is
shown in Figure 2.Discovery Analysis
We first identified mQTLs that could serve as proxies for
2,622 smoking-related CpG sites identified in a large epige-
nome-wide association study (EWAS) meta-analysis con-
ducted by the CHARGE Consortium (Table S1).3 For this,
we used a catalog of SNPs associated with CpG sites in the
ARIES study10 to identify conditionally independentmQTLs
(from genome-wide complex-trait analysis) from the mid-
dle-age time point (mean age 47.5 years, n ¼ 846).10 We
were able to proxy 474 unique CpG sites associated with
smoking (p < 1 3 107) by using at least one mQTL (96%
in cis, 4% in trans). 406 of the 474 CpGs (86%) were proxied
by a single SNP, of which 16 (4%)were in trans (Table S2). Of
these, 415 were present in a FEV1 GWAS (n¼ 321,047) con-
ducted as part of the UKBiobank study. Theminimum r2 for
anmQTLwas 2.9%, and theminimumF-statistic was 10.29,
and the mean r2 was 9.9% and mean F-statistic was 109.4,
thus indicating adequate strength of the genetic variants
for MR analysis (Table S2).
To assess the causal effect of DNA methylation at smok-
ing-related CpG sites on lung function, we looked up the
identified mQTLs in the lung-function GWAS summary
data from the UK Biobank and conducted two-sample
MR. We observed 18 CpG-FEV1 effect estimates that sur-
vived multiple-testing correction (Bonferroni p < 1.2 3
104) (Table 1, Table S3), and we found evidence for
more causal effects than would be expected on the basis
of chance (Figure S1).
Given previous findings of a mediating role of AHRR
(cg05575921) methylation in the relationship between
smoking and lung function, we specifically tested the
causal effect of methylation at cg05575921 on FEV1 in
an MR framework. Because no mQTLs were found to be
robustly associated with this CpG site in the middle age
time point of ARIES, we identified two mQTLs from the
ARIES childhood time point and carried these forward to
the MR analysis (Table S4). This revealed no strong evi-
dence for a causal effect of AHRR (cg05575921) methyl-
ation on FEV1 (Table S5).Replication Analysis
We attempted to replicate effect estimates for the top 18
CpG sites identified in the UK Biobank by using data
from the SpiroMeta GWAS meta-analysis of FEV1
(n ¼ 79,055) (Figure 3). Three CpGs (cg21201401
[LIME1/ZGPAT], cg19758448 [PGAP3], and cg126164870
Figure 2. Flowchart of the Analysis Pipe-
line, Outlining the Different Analyses Per-
formed at Each Stage of the Study
Cohorts and sample sizes used for each anal-
ysis are detailed in the flowchart.
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Stratified Analysis
The sample used in the discovery analysis included
current, former, and never smokers in the UK Biobank,
and so we performed a stratified analysis by using never-
and heavy-smoking subsets of the UK Biobank study in
the UK BiLEVE dataset. This stratified analysis had less sta-
tistical power than the discovery analysis as a result of a
10-fold drop in sample size (smokers, n ¼ 24,457; non-
smokers, n ¼ 24,474). The results from the stratified anal-
ysis are compared to the discovery analysis in Figure S2,
and Table S7 shows the results for the top CpGs. Effect es-
timates were generally similar between the mixed, smok-
ing-only, and non-smoking-only groups. For some sites
(cg09099830, cg09206294, cg15951188, cg24033122,
and cg10672416), an effect was present in smokers but
not in non-smokers, whereas at others (cg10255761,
cg0632664, cg21201401, and cg04337534), there was a
larger effect in non-smokers than in smokers.
Causal Effects of DNA Methylation on Other Lung-
Function-Related Traits
Of the CpG sites where DNAmethylation was identified as
having a putative causal role on FEV1, there was similar ev-
idence for a causal effect of DNA methylation on FVC at
15 CpG sites beyond a stringent Bonferroni threshold
(p < 0.0028) and on the FEV1/FVC ratio at eight CpG sites
(Figure S3, Table S8). Evidence for a causal effect on
lung diseases (i.e., asthma and COPD) at these sites
was not as strong, although this analysis was less well
powered (Figure S4, Table S8). Nonetheless, four CpG
sites (cg09447622, cg10672416, cg19758448, and
cg21201401) surpassed the Bonferroni threshold in rela-
tion to asthma, and the effects observed for both asthma
and COPDwere typically in the opposite direction of those
for the lung-function measures, as expected.The American Journal of HDNA Methylation and Lung
Function: Direction of Causality
We performed directionality tests by
using the MR Steiger method34 to pro-
vide evidence that the causal pathway
was in the direction fromDNAmethyl-
ation to FEV1, rather than vice versa.
This was suggested to be the case for
all CpG sites in the main analysis
(Table S9) because the mQTLs ex-plained substantially more variation in DNA methyl-
ation (between 3.3% for cg09447622 and 31.3% for
cg24033122) than in FEV1 (r
2 < 0.04%). When testing
the impact of FEV1 on DNA methylation, we used 175
out of 221 SNPs identified in the UK Biobank GWAS20 as
genetic proxies and found little evidence to suggest that
lung function had a causal effect on DNA methylation at
any of the 18 CpG sites (Table S10).
Smoking Behavior and DNA Methylation: Direction of
Causality
We also evaluated the direction of causality between life-
time smoking behavior and DNA methylation at the
identified CpG sites by using 119 out of 126 SNPs identi-
fied from a GWAS of a comprehensive smoking-index
metric29 as genetic proxies. There was limited evidence
that lifetime smoking behavior had a causal effect on
DNA methylation at the 18 CpG sites of interest, and the
effect estimate from MR analysis was consistent with the
original smoking EWAS at only 12 of the 18 CpG sites in
terms of the direction of methylation (Table S11). This
finding is in contrast to MR analysis for the majority of
the smoking-related CpG sites, where the MR estimates
were more in line with those from the smoking EWAS
(Figure S5).
Conversely, there was evidence for a causal effect of DNA
methylation on lifetime smoking at several of the CpG
sites when we performed the reciprocal MR analysis (Table
S12). We also performed directionality tests by using the
MR Steiger method, which provided evidence that the
causal pathway was in the direction from DNA methyl-
ation to smoking, rather than vice versa (Table S13).
Negative Control
Given the differences in sample sizes between the DNA
methylation and lifetime smoking datasets that may bias
the directionality tests,34 we also carried out further anal-
ysis using mQTL data from the childhood time point
(mean age 7.5 years, n ¼ 885) as a negative control. We
showed that the mQTLs were strongly associated withuman Genetics 106, 1–12, March 5, 2020 5
Table 1. Results of Two-Sample MR Analysis of the Effects on Lung Function (FEV1) of DNA Methylation at Smoking-Related CpG Sites.
CpG Chromosome Position Nearest Gene(s) Method N SNPs b SE p Value
cg12616487 11 62379063 EML3/AHNAK Wald ratio 1 0.101 0.010 3.34 3 1024
cg09447622 6 35108605 TCP11 Wald ratio 1 0.063 0.009 4.77 3 1012
cg21201401 20 62367884 LIME1/ZGPAT Wald ratio 1 0.076 0.013 1.54 3 109
cg19758448 17 37828296 PGAP3 Wald ratio 1 0.029 0.005 6.98 3 109
cg06382664 11 73098877 RELT Wald ratio 1 0.045 0.008 1.16 3 108
cg24033122 16 30485383 ITGAL Wald ratio 1 0.019 0.004 2.31 3 107
cg09099830 16 30485485 ITGAL Wald ratio 1 0.042 0.008 2.57 3 107
cg21356710 2 24234017 MFSD2B Wald ratio 1 0.030 0.006 5.19 3 107
cg10672416 12 123718706 C12orf65 Wald ratio 1 0.043 0.009 8.97 3 107
cg15059804 1 33766318 ZNF362 Wald ratio 1 0.023 0.005 2.02 3 106
cg10255761 3 49210029 KLHDC8B Wald ratio 1 0.042 0.009 2.48 3 106
cg23771366 11 86510998 PRSS23 Wald ratio 1 0.039 0.008 2.59 3 106
cg09206294 15 42072687 MAPKBP1 Wald ratio 1 0.049 0.011 2.95 3 106
cg15233611 12 122244660 SETD1B Wald ratio 1 0.051 0.011 3.09 3 106
cg19717773 7 2847554 GNA12 Inverse-variance weighted 2 0.032 0.007 6.94 3 106
cg04337534 11 65816809 GAL3ST3 Wald ratio 1 0.052 0.012 1.16 3 105
cg15951188 17 7832680 KCNAB3 Wald ratio 1 0.023 0.005 3.27 3 105
cg11660018 11 86510915 PRSS23 Wald ratio 1 0.036 0.009 5.54 3 105
Two-sampleMR analysis involving SNP-methylation estimates from ARIES (sample 1, Table S2) and SNP-FEV1 estimates from the UK Biobank (sample 2). The effect
size (b), standard error (SE), and p value for each CpG reaching significance after Bonferroni correction is reported, along with the chromosome and position of the
CpG, the nearest gene(s), the MR method used for analyzing the effect on lung function, and the number of SNPs used.
Please cite this article in press as: Jamieson et al., Smoking, DNA Methylation, and Lung Function: a Mendelian Randomization Analysis to
Investigate Causal Pathways, The American Journal of Human Genetics (2020), https://doi.org/10.1016/j.ajhg.2020.01.015DNA methylation in ARIES at the childhood time point
(i.e., in non-smoking individuals) and thereby ruled out
the possibility that the mQTLs were having their primary
effect via smoking (Table S14).
Mediation Analysis
Given the limited evidence suggesting that smoking has a
causal effect on DNAmethylation at the 18 CpG sites of in-
terest, we conducted mediation analysis to investigate the
mediating pathway from DNA methylation to lung func-
tion via lifetime smoking behavior at the seven CpG sites
where there was evidence for a causal effect of DNA
methylation on lung function, as well as smoking behavior
beyond a Bonferroni threshold (p < 0.0028) (Table S12).
We accomplished this by performing two-step MR anal-
ysis12 (Figure 1) and using the ‘‘product of coefficients’’
method35 to estimate the indirect effect of DNA methyl-
ation on lung function via lifetime smoking. For all seven
CpG sites, there was evidence of an indirect effect of
DNA methylation on lung function via lifetime smoking
(p% 0.006). Between 7.85% and 19.33% of the total effect
was found to be mediated by each of the CpG sites (Table
S15). This indirect effect was replicated for five CpG sites
when we used FEV1 GWAS summary data from SpiroMeta
(p% 0.008) (Table S16).
We also estimated the direct effect of methylation on
lung function by using an MVMR approach,36,37 and we6 The American Journal of Human Genetics 106, 1–12, March 5, 202used the ‘‘difference of coefficients’’ method35 to deter-
mine the indirect effect of DNAmethylation on lung func-
tion via lifetime smoking (Tables S17 and S18). Although
independent strength of the genetic variants for lifetime
smoking and the 18 CpG sites was deemed to be strong
(Q-statistics R 64.5), the indirect effect was estimated
with lower precision than the two-step MR analysis. In
addition, there was some evidence for heterogeneity in
the causal-effect estimates from the MVMR, which could
indicate the presence of invalid genetic variants (e.g., as a
result of horizontal pleiotropy)37 (Table S18). Nonetheless,
there was supportive evidence for an indirect effect of
methylation at two sites (cg10255761 and cg15951188)
on FEV1 via smoking in MVMR (Tables S17 and S18).
Evaluating Horizontal Pleiotropy
For the 18 CpG sites of interest, we assessed the robustness
of the causal effects to horizontal pleiotropy by using
multiple mQTLs in linkage disequilibrium (r2 < 0.8) as
proxies for each CpG site, and we incorporated the correla-
tion of the mQTLs as weights in a weighted generalized
linear-regression analysis.38 Given the presence of more
than one mQTL, we were able to perform IVW and
compared the results with those obtained from the main
analysis involving only independent mQTLs (Figure S6,
Table S19). Evidence for horizontal pleiotropy was evident
for two of the CpG sites (cg10255761 and cg21201401) on0
Figure 3. Results of MR Analysis of the Effect of Smoking-Asso-
ciated DNA Methylation on Lung Function (FEV1) in the UK Bio-
bank (Discovery) and SpiroMeta (Replication) Datasets
Effect sizes and 95% confidence intervals (CI) of the 18 significant
CpG sites from the discovery analysis are shown in blue, and the
effect sizes and CI of the same CpG sites in the replication analysis
in SpiroMeta are shown in red.
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(cg10672416, cg19758448, cg21201401, cg23771366,
and cg24033122) on the basis of the MR Egger intercept
value at a Bonferroni threshold of p < 0.0028 (Figure S7,
Table S20). After we accounted for horizontal pleiotropy,
effects at cg10672416, cg23771366, and cg24033122
were attenuated in the MR Egger regression, whereas at
cg21201401, evidence suggested a causal effect of DNA
methylation on FEV1 in the opposite direction to that esti-
mated in the other analyses (Figure S8). Effect estimates
based on the weighted median approach were largely
consistent with those from IVW.
Multiple-Trait Colocalization Analysis
For those CpG sites where there was evidence of a causal
effect on lung function, we applied a genetic colocalization
approach to determine whether the variant responsible for
influencing methylation at each CpG site was the same
variant influencing changes in lung function. Further-
more, it is likely that any true association between a CpG
site and lung function is mediated by changes to theTheexpression of nearby genes. To assess this, we applied ‘‘mo-
loc’’18 to investigate whether the variant responsible for
influencing methylation at each CpG site was the same
variant influencing changes to both nearby gene expres-
sion and lung function.17,43
There was strong evidence (based on PPAR 80%) at five
CpG sites that variation in DNAmethylation, gene expres-
sion, and FEV1 were all attributed to the same underlying
genetic variant. This included associations at cg21201401
(with ZGPAT expression [PPA ¼ 84.2%]) and cg12616487
(with AHNAK expression [PPA ¼ 88.9%]), which were
two of the CpGs where the effects on FEV1 were most
strongly replicated in SpiroMeta. This suggests that the
relationship between DNA methylation at these smok-
ing-associated CpG sites and lung function might also
involve the transcription of nearby genes, and such tran-
scription is a mechanism of effect consistent with causal-
ity. There was also strong evidence of colocalization at
four further CpG sites, although only between DNA
methylation and FEV1 (but not nearby gene expression).
Colocalization results are shown in Table S19. We note,
however, that plotting genetic effects at each of these
loci highlighted that many of them were in regions of
high linkage disequilibrium (Figure S9).Discussion
We investigated CpG sites previously associated with
smoking for their potential causal impact on lung function
by using a two-step MR framework. A discovery MR anal-
ysis involving mQTLs associated with 474 smoking-associ-
ated CpGs identified 18 CpGs with a possible causal effect
on lung function in the UK Biobank. These sites were an-
notated to genes involved in diverse biological pathways,
including neurological development (AHNAK, PGAP3),
lymphocytic function (ITGAL), apoptosis (RELT), tumor
suppression (ZGPAT), and endothelial-to-mesenchymal
transition (PRSS23). Genetic variation in ZNF362 has also
been recently implicated in relation to risk-taking propen-
sity.45 Replication in SpiroMeta provided supportive evi-
dence for a causal effect of methylation on FEV1 at three
CpG sites, although the sample size of this replication
analysis was much smaller than that performed with UK
Biobank data (79,055 versus 321,047), and there was con-
sistency in the direction of effect at 83% of the CpG sites.
A further analysis using the UK BiLEVE dataset stratified by
smoking status highlighted heterogeneity in effects among
heavy smokers compared with non-smokers at some of the
sites. 15 of the CpG sites identified in relation to FEV1 also
showed evidence for a causal effect on FVC, and eight
showed an effect on the FEV1/FVC ratio. There was also
suggestive evidence for causality on lung diseases (i.e.,
asthma and COPD).
We found little evidence to suggest that lung function in
turn influenced DNA methylation at the 18 CpG sites.
Interestingly, MR analyses also provided limited evidenceAmerican Journal of Human Genetics 106, 1–12, March 5, 2020 7
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these smoking-related sites. Instead, we observed that at
several of the CpG sites DNA methylation had a causal ef-
fect on smoking. We conducted mediation analysis by us-
ing both two-step and multivariable MR to estimate the
extent to which smokingmediates the association between
DNA methylation and lung function at these sites. In two-
step MR, we found evidence of mediation for seven CpG
sites when we used FEV1 GWAS summary data from the
UK Biobank and for five CpG sites when we used Spiro-
Meta. Indirect effects were estimated with less precision
in the MVMR approach. We also performed additional
MR analyses to investigate horizontal pleiotropy, and we
integrated evidence from gene expression in ‘‘moloc’’ to
provide further evidence for causality.
Comparison with Other Studies
We searched both the EWAS Catalog and the EWAS Atlas46
to assess whether any of the 18 CpG sites had been previ-
ously identified in other EWASs of lung function or COPD.
The CpG sites cg15059804 (ZNF362) and cg11660018
(PRSS23) were found to be associated with asthma in an
EWAS conducted in lung cells;47 cg11660018 (PRSS23)
and cg23771366 (PRSS23) were suggested to have a causal
effect on lung function in another EWAS conducted in
blood; this study was followed up by a two-sample MR
analysis.7 The direction of causal effect for these two
CpGs in this MR analysis was consistent with our results.
cg21201401 (LIME1/ZGPAT) was found to be inversely
associated with COPD in an EWAS conducted in lung tis-
sue (114 subjects with COPD and 46 controls who were
all former smokers).48 This effect is consistent with our
observation of a causal effect on increased FEV1.
As mentioned in the Introduction, one previous study
indicated that hypomethylation at cg05575921 (AHRR)
might mediate the association between smoking and lung
function.7 However, we found in MR analysis that there
was no strong evidence for a causal effect of AHRRmethyl-
ation on FEV1, indicating that it is unlikely to be mediating
the effect of smoking on lung function. Similar conflicting
findings have been observed between conventional media-
tion approaches and MR analysis aimed at determining
epigenetic mediation in the context of smoking and lung
cancer49,50 and of prenatal famine and later-life metabolic
profile.51,52 Traditional mediation approaches are more sus-
ceptible to measurement error and potential reverse causa-
tion than MR,53 meaning the proportion of the mediated
effect reported by these studies is likely to be overestimated.
However, several limitations of MR analysis have also been
raised previously and might explain discrepancies,
including tissue specificity, pleiotropy, and low power, in
these results.54 These limitations arediscussed in turnbelow.
Limitations
Sample Considerations
A possible explanation for why this MR analysis did not
detect a causal effect of smoking on DNA methylation is8 The American Journal of Human Genetics 106, 1–12, March 5, 202low power resulting from the small sample size for the
DNA methylation sample (n ¼ 846). Three of the 18 sites
identified as having a causal effect on lung function in
our analysis were also previously implicated in an EWAS
of maternal smoking in pregnancy,55 although the direc-
tion of effect was not always consistent with our results.
These were cg12616487 (EML3/AHNAK), cg23771366
(PRSS23), and cg21201401 (LIME1/ZGPAT). Because DNA
methylation is unlikely to directly influence maternal
smoking in this instance, this indicates that smoke expo-
sure (whether this be through one’s own smoking or
smoke exposure in-utero) might have a causal effect on
DNA methylation but that this effect might have been un-
detected in our MR analysis. Furthermore, the intergenera-
tional effect that maternal smoking had at these CpG sites
might have biased the negative-control analysis in that the
mQTL effect seen in childhood could have been
confounded by parental smoking and inherited mQTLs.
Furthermore, although both the GWASs for lifetime
smoking and lung function were conducted in samples
that included both males and females, the mQTL effects
used in the main analysis were obtained in females only
in ARIES. Nonetheless, we have shown consistency in
the mQTL effects in a mixed sample of males and females
from the ARIES childhood time point.
An additional sample consideration relates to the use of
both the UK Biobank and the UKBiLEVE subset, both of
which represent selected groups that could bias effect esti-
mates in the MR analysis.56 Nonetheless, we have also per-
formed independent replication by using data from 22
studies from the SpiroMeta Consortium, and these pro-
vided confirmatory causal estimates at the majority of
the identified CpG sites.
Horizontal Pleiotropy
We observed heterogeneity of causal effects for some of the
CpG sites between smokers and non-smokers. For
example, at cg10255761 (KLHDC8B) and cg21201401
(LIME1/ZGPAT), although DNA methylation was shown
to have a causal effect on smoking and lung function in
the mediation analysis, there was also evidence for a causal
effect on lung function among non-smokers. Caution over
these results is warranted, since this stratified analysis
effectively conditions on a collider (i.e., smoking status)
that might induce bias.57 However, another potential
explanation for these findings is the horizontal pleiotropy
in the MR analysis. We performed additional MR analyses
to detect and correct for this bias, and we demonstrated
that at some CpG sites, including cg21201401 (LIME1/
ZGPAT), there was evidence to suggest horizontal
pleiotropy.
Multiple-Trait Colocalization
We also performed a colocalization analysis on our top hits
to investigate the relationship between methylation of
these sites, expression of nearby genes, and variation in
lung function. If all three of these traits were to share a
common causal variant, it would suggest that associations
are more likely to be due to an underlying causal0
Please cite this article in press as: Jamieson et al., Smoking, DNA Methylation, and Lung Function: a Mendelian Randomization Analysis to
Investigate Causal Pathways, The American Journal of Human Genetics (2020), https://doi.org/10.1016/j.ajhg.2020.01.015relationship as opposed to genetic confounding (i.e., high
linkage disequilibrium between an mQTL and a variant
that influences lung function).
Our colocalization analysis revealed that genetic varia-
tion associated with DNA methylation colocalizes with
both variation in lung function and gene expression at
several sites. For example, methylation at cg21201401 was
shown to colocalize with ZGPAT expression and lung func-
tion, and methylation at cg12616487 was shown to coloc-
alize with AHNAK expression and lung function. Although
findings related to cg21201401 and ZGPAT expression
should be interpreted with caution, given the presence of
horizontal pleiotropy in theMR analysis, AHNAK is a strong
candidate for being responsible for the association of this
locus with variation in lung function. In particular, AHNAK
is responsible for a neuroblast differentiation-associated
protein that has previously been reported to confer risk of
COPD as the result of missense variants in its coding re-
gion.58 However, it should be noted that several of the
mQTLs investigated in the colocalization analysis were in
regions of high linkage disequilibrium. As such, although
the findings might be useful in prioritizingloci where epige-
netic factors putatively influence variation in lung func-
tion, functional studies will need to robustly demonstrate
this. Furthermore, evidence for a causal effect of DNA
methylation at cg12616487 (EML3/AHNAK) was replicated
in an MR analysis with data from the SpiroMeta Con-
sortium. This further supports evidence indicating that it
represents a promising candidate for being a potential mo-
lecular mediator along the causal pathway from smoking to
variation in lung function
We detected evidence of colocalization between DNA
methylation and lung function at various CpG sites, but
gene expression did not also colocalize with these. For
example, the functional gene that might be responsible
for the association at cg21356710 could be UBXN2A
because, although it is not the closest gene to the CpG
site, it has been previously implicated in nicotine meta-
bolism.59 However, strong evidence from future research
would need to support this.
Tissue Specificity
A recent study that investigated the colocalization of
mQTLs with genetic risk variants for COPD identified
several lung-tissue mQTLs that might be involved in
COPD pathogenesis.60 These findings did not overlap
with the findings of this study, perhaps because of differ-
ences in tissue type.However, because someof theCpGsites
that were causally implicated in our MR analysis might be
exerting their effect on lung functionvia smokingbehavior,
lung tissue might not always be the most relevant for
appraising causal effects. Future work should evaluate and
integrate mQTL and eQTL effects from multiple tissues to
elucidate causal effects in themost biologically relevant tis-
sues. For example, one could use lung-derived tissue to
perform an investigation similar to that undertaken in our
study in order to further evaluate the molecular mecha-
nisms that influence lung function.TheMeasurement Imprecision
One of the main limitations of mediation analysis is the
assumption of no measurement error. MR attempts to
overcome this limitation with the use of genetic variants,
which are typically measured with high accuracy. How-
ever, differential measurement precision of the pheno-
types being investigated in an MR approach can lead to
spurious findings in certain instances.
One explanation for the finding that DNA methylation
has a causal effect on smoking at several of the CpG sites
is that the SNPs used to proxy for DNA methylation have
their primary effect through smoking. We assessed this
by using the Steiger test, which indicated that this alter-
native explanation was not likely for those CpG sites
where DNA methylation had a causal effect on smoking.
However, this test is liable to return inaccurate causal di-
rections if there are large differences in sample size be-
tween the two samples or if the phenotypes have differ-
ences in measurement precision,34 which is likely to be
the case in this context. To assess this further, we
compared the magnitude of the mQTL effects in a non-
smoking subset of ARIES (children at age 7 years) and
found similar effects.Strengths
Despite these limitations, this study has several strengths,
which include the systematic evaluation of the causal ef-
fect of a large number of smoking-related CpG sites on
lung function; the replication of findings in different
smoking strata and in an independent dataset; the integra-
tion of several large-scale datasets in the evaluation of the
causal relationship between smoking, DNA methylation,
and lung function; the application of a formal two-step
MR approach in the evaluation of mediation; and the use
of a colocalization approach that integrated gene expres-
sion data.Conclusions
Using an MR approach, we identified several CpG sites
where DNA methylation might have a causal effect on
lung function, as assessed by FEV1. At some sites, there
was evidence to suggest that DNA methylation influ-
enced smoking, which in turn influenced lung function,
rather than that smoking influenced DNA methylation,
which then influenced lung function, as in the originally
proposed mechanism. The findings presented here high-
light potential therapeutic targets for improving lung
function and possibly smoking cessation, although
further studies with larger-scale and tissue-specific DNA
methylation and expression data will need to confirm
these results.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
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